HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

vanadyl-poly (gamma-glutamic acid)

Hypoglycemic Agent; structure in first source

Also Known As:

VO-gamma-PGA

Networked: 2 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Karmaker, Subarna: 2 articles (11/2007 - 09/2006)
2.	Saha, Tapan K: 2 articles (11/2007 - 09/2006)
3.	Sakurai, Hiromu: 2 articles (11/2007 - 09/2006)
4.	Yoshikawa, Yutaka: 2 articles (11/2007 - 09/2006)
5.	Yasui, Hiroyuki: 1 article (09/2006)

Related Diseases

1.	Metabolic Syndrome (Dysmetabolic Syndrome X) 11/01/2007 - "In addition, the glucose intolerance, HbA(1c) level, hyperinsulinemia, hypercholesterolemia, and hyperleptinemia were significantly improved in VO(gamma-pga)-treated KKA(y) mice compared with those treated with VS. Based on these observations, VO(gamma-pga) is proposed to be the first orally active oxovanadium(IV)-polymer complex for the efficacious treatment of not only type 2 diabetes but also metabolic syndrome in animals."
2.	Glucose Intolerance 11/01/2007 - "In addition, the glucose intolerance, HbA(1c) level, hyperinsulinemia, hypercholesterolemia, and hyperleptinemia were significantly improved in VO(gamma-pga)-treated KKA(y) mice compared with those treated with VS. Based on these observations, VO(gamma-pga) is proposed to be the first orally active oxovanadium(IV)-polymer complex for the efficacious treatment of not only type 2 diabetes but also metabolic syndrome in animals."
3.	Hyperinsulinism (Hyperinsulinemia) 11/01/2007 - "In addition, the glucose intolerance, HbA(1c) level, hyperinsulinemia, hypercholesterolemia, and hyperleptinemia were significantly improved in VO(gamma-pga)-treated KKA(y) mice compared with those treated with VS. Based on these observations, VO(gamma-pga) is proposed to be the first orally active oxovanadium(IV)-polymer complex for the efficacious treatment of not only type 2 diabetes but also metabolic syndrome in animals."
4.	Hypercholesterolemia 11/01/2007 - "In addition, the glucose intolerance, HbA(1c) level, hyperinsulinemia, hypercholesterolemia, and hyperleptinemia were significantly improved in VO(gamma-pga)-treated KKA(y) mice compared with those treated with VS. Based on these observations, VO(gamma-pga) is proposed to be the first orally active oxovanadium(IV)-polymer complex for the efficacious treatment of not only type 2 diabetes but also metabolic syndrome in animals."
5.	Type 2 Diabetes Mellitus (MODY) 11/01/2007 - "In addition, the glucose intolerance, HbA(1c) level, hyperinsulinemia, hypercholesterolemia, and hyperleptinemia were significantly improved in VO(gamma-pga)-treated KKA(y) mice compared with those treated with VS. Based on these observations, VO(gamma-pga) is proposed to be the first orally active oxovanadium(IV)-polymer complex for the efficacious treatment of not only type 2 diabetes but also metabolic syndrome in animals."

Related Drugs and Biologics

1.	Polymers
2.	oxovanadium IV
3.	Insulin (Novolin)
4.	Blood Glucose (Blood Sugar)